Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 35

The DOI matches its Crossref record.

A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of Pseudomonas aeruginosa in Patients with Bronchiectasis

Long, Merete B., Gilmour, Amy, Kehl, Margaret, Tabor, David E., Keller, Ashley E., Warrener, Paul, Gopalakrishnan, Vancheswaran, Rosengren, Sanna, Crichton, Megan L., McIntosh, Eve, Giam, Yan Hui, Keir, Holly R., Brailsford, Wayne, Hughes, Rod, Belvisi, Maria G., Sellman, Bret R., DiGiandomenico, Antonio, Chalmers, James D.·2024·American Journal of Respiratory and Critical Care Medicine

Abstract

Rationale: Pseudomonas aeruginosainfection is associated with worse outcomes in bronchiectasis. Impaired neutrophil antimicrobial responses contribute to bacterial persistence. Gremubamab is a bivalent, bispecific monoclonal antibody targeting Psl exopolysaccharide and the type 3 secretion system component PcrV. Objectives: This study evaluated the efficacy of gremubamab to enhance killing of P. aeruginosaby neutrophils from patients with bronchiectasis and to prevent P. aeruginosa–associated cytotoxicity. Methods: P. aeruginosaisolates from a global bronchiectasis cohort (n = 100) underwent whole-genome sequencing to determine target prevalence. Functional activity of gremubamab against selected isolates was tested in vitroand in vivo. Patients with bronchiectasis (n = 11) and control subjects (n = 10) were enrolled, and the effect of gremubamab in peripheral blood neutrophil opsonophagocytic killing (OPK) assays against P. aeruginosawas evaluated. Serum antibody titers to Psl and PcrV were determined (n = 30; 19 chronic P. aeruginosainfection, 11 no known P. aeruginosainfection), as was the effect of gremubamab treatment in OPK and anti–cytotoxic activity assays. Measurements and Main Results: Psl and PcrV were conserved in isolates from chronically infected patients with bronchiectasis. Seventy-three of 100 isolates had a full psllocus, and 99 of 100 contained the pcrVgene, with 20 distinct full-length PcrV protein subtypes identified. PcrV subtypes were successfully bound by gremubamab and the monoclonal antibody–mediated potent protective activity against tested isolates. Gremubamab increased bronchiectasis patient neutrophil-mediated OPK (+34.6 ± 8.1%) and phagocytosis (+70.0 ± 48.8%), similar to effects observed in neutrophils from control subjects (OPK, +30.1 ± 7.6%). No evidence of competition between gremubamab and endogenous antibodies was found, with protection against P. aeruginosa–induced cytotoxicity and enhanced OPK demonstrated with and without addition of patient serum. Conclusions: Gremubamab enhanced bronchiectasis patient neutrophil phagocytosis and killing of P. aeruginosaand reduced virulence.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.202308-1403oc

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 34

  1. Chalmers, 2018, Bronchiectasis, Nat Rev Dis Primers, 4, 45, 10.1038/s41572-018-0042-3 · DOI · Paper page
  2. Sibila, 2022, Heterogeneity of treatment response in bronchiectasis clinical trials, Eur Respir J, 59, 2100777, 10.1183/13993003.00777-2021 · DOI
  3. Dicker, 2021, The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study, Lancet Respir Med, 9, 885, 10.1016/S2213-2600(20)30557-9 · DOI · Paper page
  4. Chalmers, 2023, Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC), Lancet Respir Med, 11, 637, 10.1016/S2213-2600(23)00093-0 · DOI · Paper page
  5. Aksamit, 2017, Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry, Chest, 151, 982, 10.1016/j.chest.2016.10.055 · doi:10.1016/j.chest.2016.10.055
  6. Finch, 2015, A comprehensive analysis of the impact of Pseudomonas aeruginosacolonization on prognosis in adult bronchiectasis, Ann Am Thorac Soc, 12, 1602, 10.1513/AnnalsATS.201506-333OC · DOI · Paper page
  7. Mandsberg, 2009, Antibiotic resistance in Pseudomonas aeruginosastrains with increased mutation frequency due to inactivation of the DNA oxidative repair system, Antimicrob Agents Chemother, 53, 2483, 10.1128/AAC.00428-08 · DOI
  8. Varga, 2015, Genotypic and phenotypic analyses of a Pseudomonas aeruginosachronic bronchiectasis isolate reveal differences from cystic fibrosis and laboratory strains, BMC Genomics, 16, 883, 10.1186/s12864-015-2069-0 · DOI
  9. Polverino, 2017, European Respiratory Society guidelines for the management of adult bronchiectasis, Eur Respir J, 50, 1700629, 10.1183/13993003.00629-2017 · DOI · Paper page
  10. Laska, 2019, The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis, Lancet Respir Med, 7, 855, 10.1016/S2213-2600(19)30185-7 · DOI
  11. Chastre, 2022, Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosabispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial, Crit Care, 26, 355, 10.1186/s13054-022-04204-9 · DOI · Paper page
  12. Hauser, 2009, The type III secretion system of Pseudomonas aeruginosa: infection by injection, Nat Rev Microbiol, 7, 654, 10.1038/nrmicro2199 · DOI · Paper page
  13. DiGiandomenico, 2014, A multifunctional bispecific antibody protects against Pseudomonas aeruginosa, Sci Transl Med, 6, 262ra155, 10.1126/scitranslmed.3009655 · DOI · Paper page
  14. Tabor, 2018, Pseudomonas aeruginosaPcrV and Psl, the molecular targets of bispecific antibody MEDI3902, are conserved among diverse global clinical isolates, J Infect Dis, 218, 1983
  15. Ali, 2019, Phase 1 study of MEDI3902, an investigational anti-Pseudomonas aeruginosaPcrV and Psl bispecific human monoclonal antibody, in healthy adults, Clin Microbiol Infect, 25, 629.e1, 10.1016/j.cmi.2018.08.004 · DOI · Paper page
  16. Hilliam, 2017, Pseudomonas aeruginosaadaptation and diversification in the non-cystic fibrosis bronchiectasis lung, Eur Respir J, 49, 1602108, 10.1183/13993003.02108-2016 · DOI
  17. Bedi, 2018, Blood neutrophils are reprogrammed in bronchiectasis, Am J Respir Crit Care Med, 198, 880, 10.1164/rccm.201712-2423OC · DOI
  18. Pohl, 2014, A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy, Blood, 124, 999, 10.1182/blood-2014-02-555268 · DOI · Paper page
  19. Painter, 2008, The role of chloride anion and CFTR in killing of Pseudomonas aeruginosaby normal and CF neutrophils, J Leukoc Biol, 83, 1345, 10.1189/jlb.0907658 · DOI
  20. Bankevich, 2012, SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing, J Comput Biol, 19, 455, 10.1089/cmb.2012.0021 · DOI · Paper page
  21. Seemann, 2014, Prokka: rapid prokaryotic genome annotation, Bioinformatics, 30, 2068, 10.1093/bioinformatics/btu153 · DOI · Paper page
  22. Inouye, 2014, SRST2: rapid genomic surveillance for public health and hospital microbiology labs, Genome Med, 6, 90, 10.1186/s13073-014-0090-6 · DOI · Paper page
  23. Treangen, 2014, The Harvest suite for rapid core-genome alignment and visualization of thousands of intraspecific microbial genomes, Genome Biol, 15, 524, 10.1186/s13059-014-0524-x · doi:10.1186/s13059-014-0524-x · Paper page
  24. Letunic, 2016, Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees, Nucleic Acids Res, 44, W242, 10.1093/nar/gkw290 · DOI · Paper page
  25. Thaden, 2016, Pseudomonas aeruginosabacteremic patients exhibit nonprotective antibody titers against therapeutic antibody targets PcrV and Psl exopolysaccharide, J Infect Dis, 213, 640, 10.1093/infdis/jiv436 · DOI
  26. DiGiandomenico, 2012, Identification of broadly protective human antibodies to Pseudomonas aeruginosaexopolysaccharide Psl by phenotypic screening, J Exp Med, 209, 1273, 10.1084/jem.20120033 · DOI · Paper page
  27. Warrener, 2014, A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosain multiple animal infection models, Antimicrob Agents Chemother, 58, 4384, 10.1128/AAC.02643-14 · DOI
  28. Finck-Barbançon, 1997, ExoU expression by Pseudomonas aeruginosacorrelates with acute cytotoxicity and epithelial injury, Mol Microbiol, 25, 547, 10.1046/j.1365-2958.1997.4891851.x · DOI · Paper page
  29. Sato, 2011, Modified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosa, PLoS One, 6, e18356, 10.1371/journal.pone.0018356 · doi:10.1371/journal.pone.0018356
  30. Thanabalasuriar, 2019, Neutrophil extracellular traps confine Pseudomonas aeruginosaocular biofilms and restrict brain invasion, Cell Host Microbe, 25, 526, 10.1016/j.chom.2019.02.007 · DOI · Paper page
  31. Lynch, 2010, Polymorphisms in the Pseudomonas aeruginosatype III secretion protein, PcrV—implications for anti-PcrV immunotherapy, Microb Pathog, 48, 197, 10.1016/j.micpath.2010.02.008 · DOI
  32. O’Leary-Kelley, 2017, Nutrition support protocols: enhancing delivery of enteral nutrition, Crit Care Nurse, 37, e15, 10.4037/ccn2017650 · DOI
  33. Imamura, 2007, Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosainfection model, Eur Respir J, 29, 965, 10.1183/09031936.00147406 · doi:10.1183/09031936.00147406
  34. Haworth, 2019, Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa(ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials, Lancet Respir Med, 7, 213, 10.1016/S2213-2600(18)30427-2 · DOI · Paper page

Cited by

See all 35

Metadata

Authors
Long, M. B., Gilmour, A., Kehl, M., Tabor, D. E., Keller, A. E., Warrener, P., Gopalakrishnan, V., Rosengren, S., Crichton, M. L., McIntosh, E., Giam, Y. H., Keir, H. R., Brailsford, W., Hughes, R., Belvisi, M. G., Sellman, B. R., DiGiandomenico, A., & Chalmers, J. D.
Affiliations
  • Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom
  • Vaccine and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland
  • Translational Science and Experimental Medicine, Respiratory & Immunology, Respiratory and Immunology, and
  • Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and
  • Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2024-07-01
Volume
210
Issue
1
Pages
35-46
ISSN
  • 1073-449X
  • 1535-4970
Cited by
35
References
0
Language
en
Funders
  • AstraZeneca
  • European Respiratory Society

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of Pseudomonas aeruginosa in Patients with Bronchiectasis. https://app.cochat.ai/papers/10.1164/rccm.202308-1403oc
The paper
Long, M. B., Gilmour, A., Kehl, M., Tabor, D. E., Keller, A. E., Warrener, P., Gopalakrishnan, V., Rosengren, S., Crichton, M. L., McIntosh, E., Giam, Y. H., Keir, H. R., Brailsford, W., Hughes, R., Belvisi, M. G., Sellman, B. R., DiGiandomenico, A., & Chalmers, J. D. (2024). A Bispecific Monoclonal Antibody Targeting Psl and PcrV Enhances Neutrophil-Mediated Killing of Pseudomonas aeruginosa in Patients with Bronchiectasis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.202308-1403oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.